| 1. |
Patel MR, Conte MS, Cutlip DE, et al. Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). J Am Coll Cardiol, 2015, 65(9): 931-941.
|
| 2. |
Rooke TW, Hirsch AT, Misra S, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2013, 61(14): 1555-1570.
|
| 3. |
Olin JW, White CJ, Armstrong EJ, et al. Peripheral artery disease: evolving role of exercise, medical therapy, and endovascular options. J Am Coll Cardiol, 2016, 67(11): 1338-1357.
|
| 4. |
Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med, 2008, 358(7): 689-699.
|
| 5. |
Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation, 2015, 131(5): 495-502.
|
| 6. |
Sarode K, Spelber DA, Bhatt DL, et al. Drug delivering technology for endovascular management of infrainguinal peripheral artery disease. JACC Cardiovasc Interv, 2014, 7(8): 827-839.
|
| 7. |
Giordano A, Romano S, Mallardo M, et al. FK506 can activate transforming growth factor-beta signalling in vascular smooth muscle cells and promote proliferation. Cardiovasc Res, 2008, 79(3): 519-526.
|
| 8. |
Ong PJ, Kubo T, Watson TJ, et al. Angiographic, optical coherence tomography and histology findings from combination of a drug-coated balloon with an everolimus-eluting stent in a porcine model. Int J Cardiol, 2016, 223: 665-668.
|
| 9. |
Werk M, Langner S, Reinkensmeier B, et al. Inhibition of restenosis in femoropopliteal arteries: paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation, 2008, 118(13): 1358-1365.
|
| 10. |
Werk M, Albrecht T, Meyer DR, et al. Paclitaxel-coated balloons reduce restenosis after femoro-popliteal angioplasty: evidence from the randomized PACIFIER trial. Circ Cardiovasc Interv, 2012, 5(6): 831-840.
|
| 11. |
Scheinert D, Duda S, Zeller T, et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the prevention of femoropopliteal restenosis) trial for femoropopliteal revascularization: first-in-human randomized trial of low-dose drug-coated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv, 2014, 7(1): 10-19.
|
| 12. |
Mehrotra S, Paramasivam G, Mishra S. Paclitaxel-coated balloon for femoropopliteal artery disease. Curr Cardiol Rep, 2017, 19(2): 10.
|
| 13. |
Jia X, Zhang J, Zhuang B, et al. Acotec drug-coated balloon catheter: randomized, multicenter, controlled clinical study in femoropopliteal arteries: evidence from the AcoArt Ⅰ trial. JACC Cardiovasc Interv, 2016, 9(18): 1941-1949.
|
| 14. |
Schmidt A, Ulrich M, Winkler B, et al. Angiographic patency and clinical outcome after balloon-angioplasty for extensive infrapopliteal arterial disease. Catheter Cardiovasc Interv, 2010, 76(7): 1047-1054.
|
| 15. |
Schmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries: restenosis rate and clinical outcome. J Am Coll Cardiol, 2011, 58(11): 1105-1109.
|
| 16. |
Fanelli F, Cannavale A, Boatta E, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther, 2012, 19(5): 571-580.
|
| 17. |
Liistro F, Porto I, Angioli P, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation, 2013, 128(6): 615-621.
|
| 18. |
Wu R, Tang S, Wang M, et al. Drug-eluting balloon versus standard percutaneous transluminal angioplasty in infrapopliteal arterial disease: A meta-analysis of randomized trials. Int J Surg, 2016, 35: 88-94.
|
| 19. |
Zeller T, Baumgartner I, Scheinert D, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol, 2014, 64(15): 1568-1576.
|
| 20. |
Cassese S, Ndrepepa G, Liistro F, et al. Drug-Coated Balloons for Revascularization of Infrapopliteal Arteries: A Meta-Analysis of Randomized Trials. JACC Cardiovasc Interv, 2016, 9(10): 1072-1080.
|
| 21. |
Zeller T, Beschorner U, Pilger E, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-Ⅱ ran- domized trial (BIOTRONIK’S-first in man study of the Passeo-18 LUX drug releasing PTA balloon catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv, 2015, 8(12): 1614-1622.
|
1/5
WeChat